Expedition Therapeutics is developing EXPD-101, an oral, once‑daily DPP1 inhibitor that selectively blocks neutrophil serine protease activation to reduce airway tissue damage and disease progression in COPD and other neutrophil‑driven respiratory conditions. The drug is designed for high potency, favorable pharmacokinetics, and a strong safety profile, with Phase 1 tolerability data and a global Phase 2 trial underway. It targets pharmaceutical partners, clinical researchers, and healthcare providers seeking disease‑modifying therapies for COPD, bronchiectasis, neutrophilic asthma, and related diseases.
Funding
Funding not disclosed
Founders
Product
Problem
Chronic obstructive pulmonary disease (COPD) and other neutrophil-driven respiratory conditions lack therapies that modify disease progression by targeting the underlying neutrophilic inflammation, leaving the majority of patients without effective disease‑controlling options.
Solution
Expedition Therapeutics is developing EXPD-101, an oral, once‑daily inhibitor of dipeptidyl‑peptidase 1 (DPP1). By selectively blocking activation of neutrophil serine proteases, EXPD-101 reduces airway tissue damage and remodeling while preserving overall neutrophil function. The molecule is engineered for high potency, favorable pharmacokinetics, and a strong safety profile, demonstrated by tolerability and target engagement in Phase 1 studies. A global Phase 2 trial is underway to evaluate its efficacy in COPD, with plans to explore additional indications such as bronchiectasis and neutrophilic asthma.
Target Audience
Primary customers are pharmaceutical partners, clinical researchers, and healthcare providers focused on COPD and related neutrophilic respiratory diseases seeking disease‑modifying therapies.
Features
- Oral, once‑daily dosing format for convenient chronic administration
- Selective DPP1 inhibition that prevents activation of neutrophil serine proteases without depleting neutrophil counts
- High potency and optimized pharmacokinetic properties designed for sustained target engagement
- Demonstrated safety and clear target engagement in Phase 1 clinical testing
- Ongoing global Phase 2 trial in COPD, with expansion potential to other neutrophil‑driven respiratory diseases